Pilot Feasibility Study of Combined Kidney and Hematopoietic Stem Cell Transplantation to Cure End-stage Renal Disease

  • STATUS
    Recruiting
  • End date
    Dec 21, 2024
  • participants needed
    16
  • sponsor
    University of Zurich
Updated on 21 April 2022
kidney transplant
nephropathy
immunosuppression

Summary

This pilot study of combined kidney and hematopoietic stem cell transplantation attempts to establish a protocol to induce immunological tolerance as a new strategy to prevent renal graft rejection. If successful, this strategy would restore renal function, while avoiding the risks associated with long-term standard anti-rejection therapy, and would represent the first option to cure end-stage renal disease.

Description

Trial design This is an open-label feasibility study of combined Human Leukocyte Antigen (HLA)-matched sibling hematopoietic stem cell and kidney transplantation. The study will be performed at the University Hospital of Zurich. The pilot study will include 5 to 8 donors and 5 to 8 recipients. We expect that 4 out of 5 recipients should be off immunosuppressive therapy at 6-12 months.

Study protocol

  1. Non-study-specific interventions before transplantation Donor and recipients will be screened according to the established internal guidelines for living donor kidney and hematopoietic stem cell transplantation of the Transplantation Center of the University Hospital Zurich.
  2. Study-specific interventions before transplantation
    • Potential candidates will be informed about this study by the treating physician. Interested patients will be informed in details about the study protocol, the potential benefits and risks. The patient will have sufficient time to decide to participate to this study or to undergo standard transplantation, to read and sing the informed consent form.
    • Total lymphoid irradiation: for the optimal planning of the total lymphoid irradiation, a mapping CT will be performed 2-4 weeks before therapy and repeated on day 1 after kidney transplantation.
    • Blood draw for establishment of chimerism determination.
    • The recipient will undergo one leukapheresis procedure before starting the conditioning regimen in order to bank cells for future scientific studies.
    • Stem cell mobilization and isolation in the donor by leukapheresis will be performed according to the standard protocols of the Stem cell transplantation center of the University Hospital Zurich
    • Donor-derived hematopoietic progenitor cells will be isolated from peripheral leukocytes by positive selection (CD34+ cells) using the Magnetic-Activated Cell Sorting (MACS) technology according to SOPs of the certified hematology laboratory of the University Children's Hospital Zurich. CD34 negative cells will be analyzed by Fluorescence-Activated Cell Sorting (FACS) to determine the amount of CD3 positive cells. Stem cells and flow through will be frozen until the transplant according to standard operating procedure (SOP) at the stem cell transplantation center at the University Hospital Zurich.
    • Since irradiation might reduce fertility the possibility of sperm conservation before transplantation will be offered to male recipients.
  3. Induction protocol
    • Kidney transplantation (day 0)
    • A CT scan will be performed at day 1 after transplantation for a correct definitive plan of the irradiation protocol.
    • Immunosuppression: in the first weeks after kidney transplantation the recipients will be treated with standard immunosuppression, including methylprednisolone, prednisone, mycophenolate mofetil and cyclosporine A.
    • Additionally the patient will be treated with:

Rabbit anti-thymocyte globulin (ATG): Thymoglobuline® 1.5 mg per kg; 5 daily injections from day 0 to day 4.

Total lymphoid irradiation: 10 doses of 120 centigray (cGy) (total dose 12 Gy) each to the supradiaphragmatic lymph nodes, thymus, subdiaphragmatic lymph nodes and spleen; 10 daily doses from day 1 to day 11.

• Hematopoietic stem cell transplantation (day 11 after kidney transplantation): Infusion of isolated CD34+ hematopoietic progenitor cells (≥10x10^6 cells/kg) Additionally the patients will receive 1x10^6 CD3+ T cells / kg body weight from the CD34- fraction to promote the engraftment of hematopoietic progenitor cells (T cell add-back)

4. Immunosuppression and anti-microbial prophylaxis

  • Methylprednisolone: steroids will be rapidly tapered during the first days after transplantation. All patients will be off of steroids at day 14.
  • Mycophenolate mofetil: 2 g per day, started at day 11 (4 to 6 hours after stem cell transplantation) and discontinued 1 month after stem cell transplantation.
  • Cyclosporine A:

First 3 months: whole blood through level (C0) 250-300 µg/ml

Month 3-6: cyclosporine will be tapered and discontinued at about 6 months if following criteria will be fulfilled:

  • Sustained chimerism for at least 180 days
  • No clinical signs of rejection
  • Protocol biopsy showing no evidence of acute or chronic rejection
  • No clinical signs of graft versus host disease
  • Anti-microbial prophylaxis:

Amoxicillin/clavulanic acid 2.2 g preoperatively Sulfamethoxazole/Trimethoprim for 6 months Valganciclovir: a) low risk (D-R-) - no prophylaxis; b) intermediate risk (R+) - prophylaxis with valganciclovir 450mg once daily, starting after 1 month post transplant; c) high risk (D+R-) - prophylaxis with valganciclovir 450mg once daily, starting immediately after transplantation.

5 Post-operative monitoring

  • Donor and recipient will be followed life-long in the outpatient clinic of the nephrology division according to local practice. During immunosuppression tapering and in the first months off of immunosuppression renal function will be closely monitored for an early detection of rejection episodes. Therefore, to participate to the study the patient has to agree with a weekly creatinine testing, which might also be performed by the patient's family doctor.
  • Graft versus host disease will be monitored clinically at each regular visit as well as by measurement of liver function tests.
  • The donor will be included in the control program of stem cells donors and living kidney donors as for regular transplant procedures (national registries for living kidney and stem cell donors)
  • Chimerism level in peripheral blood will be regularly assessed
  • Kidney allograft biopsies will be performed 6 months (before withdrawing of cyclosporine
    1. and 1 year after transplantation
  • Immune reconstitution will be analyzed by FACS of peripheral blood leukocytes and additional functional assays in vitro.
  • Functional immunological tolerance will be measured in in vitro assays after 1, 2, 6, 12, 18 and 24 months. These additional tests are of scientific interest, but will not influence clinical patient management.
  • Quality of life will be assessed as routinely performed in the context of the Swiss transplant cohort study (www.stcs.ch)
  • Regular monitoring for cancer development as done after conventional transplantation (skin cancer, breast cancer, prostate cancer).

Duration of subject participation and follow-up The active portion of this trial will begin approximately 2 months prior to the transplantation and continue until 2 years post-transplant. Study-related data will be collected for a minimum of 2 years post-transplant. All subjects will be followed indefinitely for graft and patient survival in routine clinical follow-ups.

Details
Condition End Stage Renal Disease
Treatment Kidney and hematopoietic stem cell transplantation, hematopoietic stem cell, hematopoietic stem cell
Clinical Study IdentifierNCT02176434
SponsorUniversity of Zurich
Last Modified on21 April 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Patients, who are eligible for kidney transplantation
Males or females 18 - 70 years of age
Subjects must have an HLA-matched sibling donor 25-70 years of age
Men and women of reproductive potential must agree to use a reliable method of birth control
Ability to understand and provide informed consent

Exclusion Criteria

Evidence of uncontrolled active infection (including replicating HIV, Hepatitic B and Hepatitis C) as defined by
clinical syndrome consistent with viral or bacterial infection, or
fever with a clinical site of infection identified, or
microbiologically documented infection
Contraindication to therapy with any one of the proposed agents (e.g. allergy to ATG)
Serologic positivity to HIV
Women of childbearing age in whom adequate contraception cannot be maintained, pregnant women or nursing mothers
Malignancy within the past two years, for which waiting time for transplantation is required by PENN registry consult, thereby excluding non-melanoma skin cancer and carcinoma in situ of the cervix
Liver transaminases > 3 x normal value
Cardiac ejection fraction < 50% by radionuclide ventriculography or echocardiography
Forced Expiratory Volume (FEV1) < 50% predicted or corrected Diffusing Capacity for Carbon Monoxide (DLCO) < 50 % predicted
Blood group incompatibility in the host-vs-graft direction
High risk of primary kidney disease recurrence
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note